Novartis lifts full-year earnings on higher prescriptions
By Ludwig Burger FRANKFURT (Reuters) -Novartis raised its full-year earnings outlook, citing strong growth momentum after scoring a trial success for a key breast cancer drug and making progress on boosting production of a radiotherapy drug against prostate cancer. The Swiss drugmaker said in a statement on Tuesday that when excluding Sandoz, the generic-drug division that will be spun off during the second half of the year, group core operating […]